Biosimilar

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with relapsing forms of multiple sclerosis.

An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.

Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the July issue, including the cover story delving into the issue of interchangeable biosimilar switching.

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.

AUSTIN, Texas — It is critical for rheumatology providers to have a thorough grasp of biosimilarity to properly respond to patient concerns regarding biosimilars, a presenter said at the 2023 Rheumatology Nurses Society annual conference.

The hotly debated topic of interchangeability between biologics and biosimilars has officially leapt from the hypothetical realm to clinical practice, ushering in a new era of therapy switching in rheumatology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

Formycon and Klinge Biopharma have submitted a biologics license application for FYB203, a biosimilar for Eylea, to the FDA, according to a press release.

Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing.